Goldman Sachs
CRNX icon

Goldman Sachs’s Crinetics Pharmaceuticals CRNX Stock Holding History

Goldman Sachs’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22.8M Buy
628,155
+61,028
+11% +$2.73M ﹤0.01% 2305
2025
Q4 		$26.4M Sell
567,127
-146,003
-20% -$6.5M ﹤0.01% 2107
2025
Q3 		$29.7M Sell
713,130
-187,757
-21% -$6M ﹤0.01% 1877
2025
Q2 		$25.9M Buy
900,887
+401,293
+80% +$12.4M ﹤0.01% 1894
2025
Q1 		$16.8M Sell
499,594
-221,675
-31% -$8.28M ﹤0.01% 2194
2024
Q4 		$36.9M Sell
721,269
-65,759
-8% -$3.68M 0.01% 1555
2024
Q3 		$40.2M Buy
787,028
+137,838
+21% +$7.11M 0.01% 1426
2024
Q2 		$29.1M Sell
649,190
-214,917
-25% -$9.92M ﹤0.01% 1561
2024
Q1 		$40.4M Buy
864,107
+213,934
+33% +$8.37M 0.01% 1299
2023
Q4 		$23.1M Buy
650,173
+97,575
+18% +$2.99M ﹤0.01% 1770
2023
Q3 		$16.4M Sell
552,598
-62,248
-10% -$1.28M ﹤0.01% 1974
2023
Q2 		$11.1M Buy
614,846
+94,648
+18% +$1.89M ﹤0.01% 2345
2023
Q1 		$8.35M Buy
520,198
+386,882
+290% +$7.16M ﹤0.01% 2580
2022
Q4 		$2.44M Buy
133,316
+10,648
+9% +$188K ﹤0.01% 3789
2022
Q3 		$2.41M Buy
122,668
+25,215
+26% +$514K ﹤0.01% 3819
2022
Q2 		$1.82M Sell
97,453
-13,150
-12% -$262K ﹤0.01% 4124
2022
Q1 		$2.43M Buy
110,603
+49,083
+80% +$993K ﹤0.01% 4078
2021
Q4 		$1.75M Buy
61,520
+6,095
+11% +$150K ﹤0.01% 4360
2021
Q3 		$1.17M Sell
55,425
-5,380
-9% -$113K ﹤0.01% 4620
2021
Q2 		$1.15M Sell
60,805
-61,547
-50% -$1.08M ﹤0.01% 4659
2021
Q1 		$1.87M Sell
122,352
-5,830
-5% -$90.4K ﹤0.01% 4055
2020
Q4 		$1.81M Buy
128,182
+26,790
+26% +$373K ﹤0.01% 3803
2020
Q3 		$1.59M Buy
101,392
+87,349
+622% +$1.34M ﹤0.01% 3735
2020
Q2 		$246K Buy
+14,043
New +$239K ﹤0.01% 4713
2019
Q4 		– Sell
-72,640
Closed -$1.09M – 5236
2019
Q3 		$1.09M Sell
72,640
-108,350
-60% -$2.11M ﹤0.01% 3971
2019
Q2 		$4.53M Buy
180,990
+166,599
+1,158% +$4.13M ﹤0.01% 2921
2019
Q1 		$328K Buy
14,391
+3,417
+31% +$84K ﹤0.01% 4589
2018
Q4 		$329K Buy
+10,974
New +$309K ﹤0.01% 4589

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Goldman Sachs's CRNX Position: Q1 2026 in Review

Goldman Sachs increased its Crinetics Pharmaceuticals (CRNX) stake by 11% in Q1 2026, buying an estimated $2.73M and bringing the position to 628,155 shares worth $22.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2305.

Goldman Sachs first reported a position in CRNX in Q4 2018 and has held it in 28 quarters since. The position peaked at $40.4M in Q1 2024. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Goldman Sachs held 628,155 shares of Crinetics Pharmaceuticals worth $22.8M as of Q1 2026.
  • Goldman Sachs bought 61,028 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $2.73M.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2305 holding.
  • Goldman Sachs first reported a position in Crinetics Pharmaceuticals in Q4 2018 and has held it in 28 quarters since.
  • Goldman Sachs's Crinetics Pharmaceuticals position peaked at $40.4M in Q1 2024.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.